Navigation Links
Emory Eye Center Implants Its First Retinal Chips In Patients With Retinitis Pigmentosa

An expanded clinical trial conducted by Optobionics Corporation involving the implantation of a retina mircrochip has allowed Emory Eye Center and the Atlanta Veterans Affairs Rehabilitation Research & Development Center to implant the device in several patients. The patients all have retinitis pigmentosa with moderate-to-severe vision loss. Three centers in the United States have been chosen to conduct the expanded trial. Other than Emory and the VA Rehabilitation R&D Center they include Rush University Medical Center's Department of Ophthalmology and the Wilmer Eye Institute at Johns Hopkins Medical Center.

Retinitis pigmentosa is a pathologic condition that is hereditary and causes progressive retinal degeneration in both eyes. It is a general term for a number of diseases that predominantly affect the photoreceptor layer or "light sensing" cells of the retina. Night blindness develops, usually in childhood, followed by loss of peripheral visual field, progressing over many years to tunnel vision and finally blindness.

At Emory Eye Center retina specialists Thomas M. Aaberg, Sr. and Jiong Yan performed the surgery recently on five patients. Another two patients are planned for mid-February.

"This experimental device may make it possible for those with retinitis pigmentosa to have a much better quality of life," says Dr. Aaberg. "We are excited to be able to participate in this clinical trial as part of Emory Eye Center's ongoing research and surgical procedures to fight blinding eye disease. Because Emory and the Atlanta VA Rehabilitation R&D Center met the FDA and Optobionics criteria that included surgical expertise, a strong research component and an established patient base of degenerative retinal diseases, we were able to be a part of this important study."

Pre- and post-surgery patients are evaluated by a team of researchers working at the Eye Center and the VA Rehabilitation R&D Center including Ronald A. Schu chard, PhD and Claire Barnes, PhD.

"This clinical trial will help evaluate the potential of Optobionics' ASR® device to provide improved functional vision or to at least slow down the progressive vision loss" says Dr. Schuchard, principal investigator for the project. "There are very few vision rehabilitative options for patients with retinal degenerative diseases, so the opportunity to be part of evaluating an experimental rehabilitative intervention for these patients is very exciting."


'"/>

Source:Emory University Health Sciences Center


Related biology news :

1. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
2. Fox Chase Cancer Center scientists identify immune-system mutation
3. Massey Cancer Center researcher helps to identify a piece of the cancer puzzle
4. $6.5 Million Grant for Microarray Center at Yale School of Medicine
5. Woods Hole Research Center plans controlled burn in Amazon rainforest
6. VCU Massey Cancer Center study shows enzyme linked to spread of breast cancer cells
7. Center releases new public survey on stem cells
8. World Trade Center identifications pushed forensic DNA technology
9. VCU Massey Cancer Center researchers identify a new class of anti-cancer drugs based on platinum
10. Mayo Clinic Cancer Center: Harnessing the measles virus to attack cancer
11. Timing is everything: First step in protein building revealed
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... , June 2, 2016   The Weather Company , ... Watson Ads, an industry-first capability in which consumers will be ... able to ask questions via voice or text and receive ... Marketers have long sought an advertising ... that can be personal, relevant and valuable; and can scale ...
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of ... the latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Medical Display- Ampronix News ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology: